Hello everyone. I am Yosuke Tochihara, CEO since October 2022. Our company is a drug discovery venture that is commercializing the excellent research seeds (research on periostin variants) of Osaka University and is advancing research and clinical development.
I started my career at a pharmaceutical company, but I am not a science graduate, having graduated from the Faculty of Economics and qualified as a certified public accountant. In that sense, I believe my mission is to lead the business to success from a non-science perspective through overall timeline and budget management and business development activities.
Our mission is to bring to the world a therapeutic drug based on the wonderful seeds (a protein derived from the periosteum that has the potential to be applied to various intractable diseases) that the founders, Professor Yoshiaki Taniyama and Associate Professor Fumihiro Sanada of Osaka University, have been researching with passion for many years.
In order to achieve this mission, it is necessary to secure the funds necessary for clinical development, promote the business, seek out partner companies, and set a course for a sustainable company (business) through listing (or M&A). Ultimately, we will continue to work hard in the belief that by advancing our business with the aim of becoming a global specialty pharmaceutical company, we will be able to deliver therapeutic drugs to patients suffering from intractable diseases and contribute to solving social problems.

Periotherapia Co., Ltd.
President and Chief Financial Officer
Yosuke Tochihara

We are developing new treatments for intractable diseases that have no known cure.
In October 2017, we established a venture company based at Osaka University that will work alongside patients around the world suffering from intractable diseases and develop much-needed treatments.
Having worked at a hospital with a tertiary emergency medical system for cardiovascular diseases, I felt the importance of a treatment to prevent heart failure after a myocardial infarction, and began basic research at the Osaka University School of Medicine. Over the past 20 years, I have believed that “where there is a will, there is a way”. Although the research started from scratch, we discovered that an important target related to chronic inflammation was a change in gene splicing variants through our own comprehensive analysis, and we created our own drug and obtained an international patent. First, we are planning to apply it clinically as a new treatment for triple-negative breast cancer, for which there is currently no treatment. In addition, we are considering applying it to the treatment of highly metastatic malignant tumors, the prevention of heart failure after myocardial infarction, diabetic retinopathy, chronic renal failure, etc. We want to create drugs that can be used in clinical practice, rather than just being used for research. Based on the above philosophy, we aim to be a company that is widely supported by society, so we would like to ask for your continued understanding and support.

Periotherapia Co., Ltd.
Director and Founder
Yoshiaki Taniyama